Bradley A. McGregor, MD
Since the frontline approval of nivolumab (Opdivo) combined with ipilimumab (Yervoy) for the treatment of patients with intermediate- and poor-risk advanced renal cell carcinoma (RCC), additional combination strategies—evaluating TKIs with checkpoint inhibitors—have come forth that are transforming treatment options once again.
Specifically, in April 2019, the FDA approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced RCC. Moreover, the agency granted a priority review designation to a supplemental biologics license application for the combination of avelumab (Bavencio) and axitinib (Inlyta) in the same patient population. With these novel regimens come unique adverse events (AEs), as well as dosage schedules and administration methods, said Bradley McGregor, MD, adding that treatment selection needs to be done on an individualized basis.
... to read the full story